Greater relative and absolute risk reduction in high-risk subgroup with previous MI treated with PCSK9 inhibition

Media formats available:

Positive lesson from a negative trial comparing peri-operative continuation or interruption of DOAC therapy
Positive lesson from a negative trial comparing peri-operative continuation or interruption of DOAC therapy
AHA 2017
Positive lesson from a negative trial comparing peri-operative continuation or interruption of DOAC therapy
- David H. Birnie, MD
New ACC/AHA hypertension guidelines empasize risk assessment
New ACC/AHA hypertension guidelines empasize risk assessment
AHA 2017
New ACC/AHA hypertension guidelines empasize risk assessment
- Prof. Clyde Yancy
More insight into effects of treatment with PCSK9 inhibition from 5 new FOURIER analyses
More insight into effects of treatment with PCSK9 inhibition from 5 new FOURIER analyses
AHA 2017
More insight into effects of treatment with PCSK9 inhibition from 5 new FOURIER analyses
Target for BP lowering differs between Europe and USA
Target for BP lowering differs between Europe and USA
AHA 2017
Target for BP lowering differs between Europe and USA
- Prof. Clyde Yancy

PACE-CME